<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="preprint">
<?all-math-mml yes?>
<?use-mml?>
<?origin ukpmcpa?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">bioRxiv</journal-id>
<journal-title-group>
<journal-title>bioRxiv : the preprint server for biology</journal-title>
</journal-title-group>
<issn pub-type="ppub"/>
</journal-meta>
<article-meta>
<article-id pub-id-type="manuscript">EMS136378</article-id>
<article-id pub-id-type="doi">10.1101/2021.10.07.463234</article-id>
<article-id pub-id-type="archive">PPR405145</article-id>
<article-version article-version-type="publisher-id">2</article-version>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>High-throughput Activity Assay for Screening Inhibitors of the SARS-CoV-2 Mac1 Macrodomain</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Dasovich</surname>
<given-names>Morgan</given-names>
</name>
<aff id="A1">Department of Chemistry, Krieger School of Arts and Sciences, Johns Hopkins University, Baltimore, Maryland 21218, United States; Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland 21205, United States</aff>
</contrib>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Zhuo</surname>
<given-names>Junlin</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Goodman</surname>
<given-names>Jack A.</given-names>
</name>
</contrib>
<aff id="A2">Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland 21205, United States</aff>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Thomas</surname>
<given-names>Ajit</given-names>
</name>
<aff id="A3">Johns Hopkins Drug Discovery, Baltimore, Maryland 21205, United States</aff>
</contrib>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>McPherson</surname>
<given-names>Robert Lyle</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jayabalan</surname>
<given-names>Aravinth Kumar</given-names>
</name>
</contrib>
<aff id="A4">Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland 21205, United States</aff>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Busa</surname>
<given-names>Veronica F.</given-names>
</name>
<aff id="A5">Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland 21205, United States; McKusick-Nathans Department of Genetics Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland 21205, United States</aff>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cheng</surname>
<given-names>Shang-Jung</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Murphy</surname>
<given-names>Brennan A.</given-names>
</name>
</contrib>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Redinger</surname>
<given-names>Karli R.</given-names>
</name>
<aff id="A6">Center for Global Health and Diseases, Case Western Reserve University, Cleveland, Ohio 44106, United States</aff>
</contrib>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Tsukamoto</surname>
<given-names>Takashi</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Slusher</surname>
<given-names>Barbara</given-names>
</name>
<aff id="A7">Johns Hopkins Drug Discovery, Baltimore, Maryland 21205, United States; Department of Neurology, School of Medicine, Johns Hopkins University, Baltimore, Maryland 21205, United States</aff>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bosch</surname>
<given-names>Jürgen</given-names>
</name>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wei</surname>
<given-names>Huijun</given-names>
</name>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Leung</surname>
<given-names>Anthony K. L.</given-names>
</name>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
</contrib-group>
<author-notes>
<corresp id="CR1">
<bold>Corresponding Authors: Jürgen Bosch</bold> – Center for Global Health and Diseases, Case Western Reserve University, Cleveland, Ohio 44106, United States; InterRayBio, LLC, Baltimore, Maryland 21205, United States; <bold>Huijin Wei</bold> – Johns Hopkins Drug Discovery, Baltimore, Maryland 21205, United States; Department of Neurology, School of Medicine, Johns Hopkins University, Baltimore, Maryland 21205, United States; <bold>Anthony K. L. Leung</bold> – Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland 21205, United States; McKusick-Nathans Department of Genetics Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland 21205, United States; Department of Oncology, School of Medicine, Johns Hopkins University, Baltimore, Maryland 21205, United States; Department of Molecular Biology and Genetics, School of Medicine, Johns Hopkins University, Baltimore, Maryland 21205, United States</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>09</day>
<month>10</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="preprint">
<day>07</day>
<month>10</month>
<year>2021</year>
</pub-date>
<permissions>
<ali:free_to_read/>
<license>
<ali:license_ref>https://europepmc.org/downloads/openaccess</ali:license_ref>
<license-p>This preprint is made available via the <ext-link ext-link-type="uri" xlink:href="https://europepmc.org/downloads/openaccess">Europe PMC open access subset</ext-link>, for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original preprint source.</license-p>
</license>
</permissions>
<abstract>
<p id="P1">Macrodomains are a class of conserved ADP-ribosylhydrolases expressed by viruses of pandemic concern, including coronaviruses and alphaviruses. Viral macrodomains are critical for replication and virus-induced pathogenesis; therefore, these enzymes are a promising target for antiviral therapy. However, no potent or selective viral macrodomain inhibitors currently exist, in part due to the lack of a high-throughput assay for this class of enzymes. Here, we developed a high-throughput ADP-ribosylhydrolase assay using the SARS-CoV-2 macrodomain Mac1. We performed a pilot screen which identified dasatinib and dihydralazine as ADP-ribosylhydrolase inhibitors. Importantly, dasatinib does not inhibit MacroD2, the closest Mac1 homolog in humans. Our study demonstrates the feasibility of identifying selective inhibitors based on ADP-ribosylhydrolase activity, paving the way for screening large compound libraries to identify improved macrodomain inhibitors and explore their potential as antiviral therapies for SARS-CoV-2 and future viral threats.</p>
</abstract>
</article-meta>
</front>
<body>
<p id="P2">Seven human coronaviruses have been identified: HCoV-229E, HCoV-NL63, HCoV-OC43 and HCoV-HKU1 are responsible for annual bouts of common cold while SARS-CoV, SARS-CoV-2, and MERS-CoV can cause severe pneumonia and are a major public health concern. Hundreds of additional coronaviruses are circulating in animal reservoirs and could be transmitted to humans.<sup>
<xref ref-type="bibr" rid="R1">1</xref>
</sup> The diseases that result from zoonotic transfer are unpredictable, but historically are severe, highly contagious, and have potentially devastating consequences for public health. Therefore, developing broad-spectrum therapeutics against corona-viruses is of timely importance and will prepare us for future epidemics.</p>
<p id="P3">The SARS-CoV-2 genome encodes four structural proteins, nine accessory proteins, and 16 nonstructural proteins that are responsible for virus replication. COVID-19 antiviral development has focused on repurposing existing drugs to inhibit the enzymatic activities of proteins involved in SARS-CoV-2 replication, including viral RNA polymerases and proteases.<sup>
<xref ref-type="bibr" rid="R2">2</xref>
</sup> As was the case for HIV and Hepatitis C virus, an effective treatment for SARS-CoV-2 will likely require a combination of drugs to pre-empt possible drug resistance. Therefore, identifying mechanistically distinct targets will complement current drug development efforts. Here we focus on screening for inhibitors of Mac1, a conserved macrodomain ADP-ribosylhydrolase within non-structural protein 3 (nsp3).</p>
<p id="P4">Macrodomain is a protein fold found in humans and pathogens.<sup>
<xref ref-type="bibr" rid="R3">3</xref>–<xref ref-type="bibr" rid="R5">5</xref>
</sup> Nearly all of them bind to adenosine diphosphate ribose (ADP-ribose).<sup>
<xref ref-type="bibr" rid="R4">4</xref>–<xref ref-type="bibr" rid="R7">7</xref>
</sup> Recent data revealed that a subset of macrodomains hydrolyzes protein-conjugated ADP-ribose.<sup>
<xref ref-type="bibr" rid="R8">8</xref>–<xref ref-type="bibr" rid="R13">13</xref>
</sup> For example, SARS-CoV, SARS-CoV-2 and MERS-CoV contain two to three macrodomains in tandem, where only the first one (called Mac1) possesses ADP-ribosylhydrolase activity.<sup>
<xref ref-type="bibr" rid="R13">13</xref>–<xref ref-type="bibr" rid="R17">17</xref>
</sup> Notably, key residues critical for ADP-ribosylhydrolase activity are 100% conserved in all seven human coronaviruses as well as those identified from animal reservoirs, such as bat (<xref ref-type="supplementary-material" rid="SD3">Fig. S1</xref>). Macrodomain ADP-ribosylhydrolases are also conserved in another genus of pathogenic RNA viruses called alphaviruses (e.g. Chikungunya virus).<sup>
<xref ref-type="bibr" rid="R11">11</xref>,<xref ref-type="bibr" rid="R12">12</xref>
</sup> Genetic evidence demonstrates the ADP-ribosylhydrolase activity of viral macrodomains is critical for replication and virulence.<sup>
<xref ref-type="bibr" rid="R11">11</xref>,<xref ref-type="bibr" rid="R13">13</xref>,<xref ref-type="bibr" rid="R18">18</xref>–<xref ref-type="bibr" rid="R21">21</xref>
</sup> Mutant coronaviruses and alphaviruses cannot replicate when the ADP-ribose-binding sites within their macrodomains are disrupted.<sup>
<xref ref-type="bibr" rid="R11">11</xref>,<xref ref-type="bibr" rid="R21">21</xref>
</sup> Additionally, macrodomain mutant viruses exhibit attenuated replication in differentiated cells and decreased virulence <italic>in vivo</italic>.<sup>
<xref ref-type="bibr" rid="R4">4</xref>,<xref ref-type="bibr" rid="R5">5</xref>
</sup> Therefore, drugs targeting the ADP-ribosylhydrolase activity of viral macrodomains have the potential to inhibit viral replication and pathogenesis.</p>
<p id="P5">Two major challenges must be addressed during the development of antiviral macrodomain inhibitors. First, measurements of macrodomain ADP-ribosylhydrolase activity have historically relied on gel-based autoradiography and western blot assays that are not practical for screening large numbers of compounds. Second, humans express 11 proteins with macrodomain folds, such as MacroD2, which is the closest enzymatically-active human homolog of SARS-CoV-2 Mac1.<sup>
<xref ref-type="bibr" rid="R15">15</xref>
</sup> Therefore, compounds that non-specifically inhibit human macrodomains will likely have off-target effects that limit their utility. Here we describe a quantitative, high-throughput assay that identified virus-specific and general inhibitors of macrodomains.</p>
<sec id="S1" sec-type="results | discussion">
<title>Results and Discussion</title>
<p id="P6">To explore whether selective inhibition of a viral macrodomain is possible, we began our investigation by identifying biochemical and structural differences between SARS-CoV-2 Mac1 and human MacroD2. Sequence analyses classified both Mac1 and MacroD2 macrodomains to the macroD-type subclass, which also includes the macrodomain from the Chikungunya virus.<sup>
<xref ref-type="bibr" rid="R3">3</xref>,<xref ref-type="bibr" rid="R5">5</xref>
</sup> Given that the Chikungunya virus macrodomain hydrolyzes ADP-ribose from recombinant PARP10 catalytic domain<sup>
<xref ref-type="bibr" rid="R11">11</xref>,<xref ref-type="bibr" rid="R12">12</xref>
</sup> and G3BP1 protein from cells,<sup>
<xref ref-type="bibr" rid="R22">22</xref>
</sup> we tested these substrates with Mac1 and MacroD2 (<xref ref-type="fig" rid="F1">Fig. 1A</xref> and S2A). Following macrodomain incubation, comparable losses of ADP-ribose signal from PARP10<sup>CD</sup> and G3BP1 were observed, indicating both SARS-CoV-2 Mac1 and human MacroD2 are active ADP-ribosylhydrolases.</p>
<p id="P7">To quantitatively measure the enzymatic activity with a high-throughput method, we developed the luminescence-based assay ADPr-Glo (<xref ref-type="fig" rid="F1">Fig. 1B</xref>): First, ADP-ribose is released from a defined protein substrate by the macrodomain ADP-ribosylhydrolase. Second, the phosphodiesterase NudF cleaves the released ADP-ribose into phosphoribose and AMP. Finally, AMP is converted to luminescence with the commercially available AMP-Glo kit. This method takes advantage of the substrate selectivity of NudF, which cleaves free ADP-ribose but has no activity with protein-conjugated ADP-ribose.<sup>
<xref ref-type="bibr" rid="R23">23</xref>
</sup> Therefore, the luminescence signal is controlled by the rate of the ADP-ribosylhydrolase. ADPr-Glo can be performed in 384-well plates with reaction volumes as low as 5 μL, greatly minimizing time and costs compared to gel-based activity assays.</p>
<p id="P8">We first used ADPr-Glo to measure the Michaelis-Menten kinetics of SARS-CoV-2 Mac1 and human MacroD2 with an ADP-ribosylated protein substrate. The K<sub>M</sub> of Mac1 was 178.5 ± 53.2 μM with a k<sub>cat</sub> of 2.1 ± 0.6 sec<sup>-1</sup> (<xref ref-type="fig" rid="F1">Fig. 1C</xref>), and the K<sub>M</sub> of MacroD2 was 9.9 ± 4.6 μM with a k<sub>cat</sub> of 0.6 ± 0.03 sec<sup>-1</sup> (<xref ref-type="fig" rid="F1">Fig. 1D</xref>). The lower K<sub>M</sub> of MacroD2 is consistent with its higher affinity for ADP-ribose monomers<sup>
<xref ref-type="bibr" rid="R16">16</xref>
</sup> and polymers (<xref ref-type="fig" rid="F1">Fig. 1E</xref> and <xref ref-type="supplementary-material" rid="SD3">S2B</xref>). Therefore, SARS-CoV-2 Mac1 and human MacroD2 exhibit distinct binding and kinetic properties with free and protein-conjugated ADP-ribose, which likely reflect chemical and structural differences within their active sites.</p>
<p id="P9">Comparison of the published macrodomain structures of Mac1 and MacroD2 revealed that ~60% of residues at the ADP-ribose binding sites are conserved (<xref ref-type="fig" rid="F1">Fig. 1F</xref>). Similar to MacroD2 and the Chikungunya virus macrodomain,<sup>
<xref ref-type="bibr" rid="R9">9</xref>,<xref ref-type="bibr" rid="R11">11</xref>
</sup> mutation of a conserved glycine residue to glutamate (G252E for SARS-CoV-2 nsp3, <xref ref-type="supplementary-material" rid="SD3">Fig. S1</xref>) abrogates the activity of Mac1 (<xref ref-type="supplementary-material" rid="SD3">Fig. S2C</xref>). Incubation of Mac1 G252E with the ADP-ribosylated protein substrate followed by NudF addition yielded the same amount of signal as the NudF-only control. A closer examination of Mac1 and MacroD2 structures revealed less conserved regions (e.g., the adenosine binding pocket; <xref ref-type="fig" rid="F1">Fig. 1F</xref>) and distinctive electrostatic surfaces surrounding the active site where ADP-ribose binds (<xref ref-type="supplementary-material" rid="SD3">Fig. S2D</xref>). Compared with MacroD2, Mac1 possesses a binding pocket with more charged surfaces that is 450 Å<sup>3</sup> larger (<xref ref-type="fig" rid="F1">Fig. 1G</xref> and <xref ref-type="supplementary-material" rid="SD3">S2D-E</xref>). Taken together, these functional and structural differences may permit selective inhibition of SARS-CoV-2 Mac1, but not human MacroD2.</p>
<p id="P10">We next established ADPr-Glo conditions for inhibitor screening (<xref ref-type="fig" rid="F2">Fig. 2A</xref>). The reaction was linear with respect to enzyme concentration (0.5 nM) and time of incubation (60 min) at room temperature in the presence of 20 μM ADP-ribosylated substrates, 125 nM NudF and final DMSO concentration of 1%, with excellent reproducibility when performed over different dates (<xref ref-type="supplementary-material" rid="SD3">Fig. S3</xref>). We then carried out a pilot screen of the 3,233 pharmacologically active compounds derived from the Selleck-FDA library (1,953) and the LOPAC library (1,280).</p>
<p id="P11">The pilot screen parameters were suitable for a large high-throughput screen with the coefficient of variation (CV) ranging from 1-4%, the screening window coefficient Z’ at 0.86, and an average signal-to-background (S/B) ratio of 3.4 (<xref ref-type="fig" rid="F2">Fig. 2B</xref>). We calculated the average signal (A) and standard deviation (SD) of compound-treated wells in each plate and determined a Z score for each compound where Z=(signal-A)/SD (<xref ref-type="fig" rid="F2">Fig. 2C</xref>). Compounds with Z score ≤ -3 were considered hits (<xref ref-type="supplementary-material" rid="SD2">Supplementary Datafile 1</xref>).</p>
<p id="P12">Our pilot screen at 100 μM identified 21 compounds from the Selleck-FDA library and 16 compounds from the LOPAC library with Z ≤ -3, resulting in a 1.2% hit rate. Notably, the kinase inhibitor dasatinib was present as three different forms in the FDA library (<xref ref-type="supplementary-material" rid="SD2">Supplementary Datafile 1</xref>), and all of them were identified as hits, indicating assay reproducibility. Among 37 total hits, 24 were excluded based on several criteria, including the presence of pan-assay interfering (PAINS) substructures and/or potential aggregators based on the ZINC filtering algorithm<sup>
<xref ref-type="bibr" rid="R24">24</xref>
</sup>, interference of luminescence detection, high-molecular weight, instrument issues or commercial availability (see <xref ref-type="supplementary-material" rid="SD2">Supplementary Datafile 1</xref>). The remaining 13 hits were either purchased in powder form or synthesized for further evaluation.</p>
<p id="P13">To identify false-positive hits that either inhibit NudF or interfere with AMP detection by AMP-Glo, we performed a counter screen where 2 μM ADP-ribose was used instead of the ADP-ribosylated substrate and the macrodomain was omitted from the reaction (<xref ref-type="supplementary-material" rid="SD3">Fig. S4A-F</xref>). Four compounds demonstrated dose-dependent inhibition in the counter screen, indicating they are inhibitors of NudF and/or AMP-Glo (<xref ref-type="supplementary-material" rid="SD3">Fig. S4B-E</xref>). Vandetanib had poor solubility in aqueous solution (&lt;10 μM) which prohibited dose-response analysis. The remaining six compounds did not inhibit the NudF-mediated counter screen assay and were subsequently evaluated in a dose-response assay against SARS-CoV-2 Mac1 (<xref ref-type="supplementary-material" rid="SD3">Fig. S4F-I</xref>).</p>
<p id="P14">Among the six remaining hits, only dasatinib and dihydralazine exhibited dose-dependent inhibition (<xref ref-type="fig" rid="F3">Fig. 3A-B</xref> and <xref ref-type="supplementary-material" rid="SD3">S4G-I</xref>), with an IC<sub>50</sub> of 37.5–57.5 μM and 485–757 μM (95% C.I.), respectively. We then evaluated these two inhibitors in an orthogonal gel-based activity assay. Consistent with its higher potency, only dasatinib mitigated the reduction of ADP-ribosylation under the tested conditions (<xref ref-type="fig" rid="F3">Fig. 3C</xref>).</p>
<p id="P15">To evaluate whether these drugs broadly inhibit ADP-ribosylhydrolases or are specific for Mac1, we replaced the SARS-CoV-2 macrodomain with human MacroD2 in our ADPr-Glo assay and tested for dose-dependent inhibition (<xref ref-type="fig" rid="F3">Fig. 3A-B</xref>). Strikingly, dasatinib did not show any inhibition of MacroD2 even at 2 mM, the solubility limit of the compound in 2% DMSO. On the contrary, dihydralazine inhibited MacroD2 and Mac1 with comparable potency (IC<sub>50</sub> = 500-1,830 μM, <italic>P</italic> = 0.82, t-test).</p>
<p id="P16">Because dasatinib was more potent and selective, we focused our efforts on investigating the dasatinib-macrodo-main interaction. To directly assess the dasatinib binding to these two macrodomains, we performed Surface Plasmon Resonance (SPR) analyses. Both Mac1 and MacroD2 bound strongly to ADP-ribose (<xref ref-type="fig" rid="F3">Fig. 3D</xref> and <xref ref-type="supplementary-material" rid="SD3">S5</xref>), indicating that both macrodomains were properly folded and able to interact with small-molecule ligands in our SPR assays. Consistent with the selective inhibition observed in the ADPr-Glo assay, dasatinib bound ~3-fold more to Mac1 than MacroD2 (<xref ref-type="fig" rid="F3">Fig. 3E</xref> and <xref ref-type="supplementary-material" rid="SD3">S5</xref>). Molecular docking analyses revealed that dasatinib binds at the highly conserved ADP-ribose binding site (<xref ref-type="fig" rid="F3">Fig. 3F-H</xref> and <xref ref-type="supplementary-material" rid="SD3">S6</xref>, Supporting Datafile 2), which is supported by the lack of ADP-ribose and dasatinib binding by the active site mutant G252E (<xref ref-type="fig" rid="F3">Fig. 3D-F</xref> and <xref ref-type="supplementary-material" rid="SD3">S5</xref>). Notably, ten of 25 dasatinib-contacting residues in Mac1 are not conserved in MacroD2 (<xref ref-type="fig" rid="F3">Fig. 3G</xref>), which may explain the selectivity.</p>
<p id="P17">Recent high-throughput efforts have used virtual and binding screens to identify compounds and fragments that bind to SARS-CoV-2 Mac1.<sup>
<xref ref-type="bibr" rid="R25">25</xref>–<xref ref-type="bibr" rid="R27">27</xref>
</sup> We directly compared dasatinib to the hits identified in these studies and found that dasatinib was a more potent ADP-ribosylhydrolase inhibitor (<xref ref-type="fig" rid="F3">Fig. 3I</xref> and <xref ref-type="supplementary-material" rid="SD3">S7A</xref>) and a stronger Mac1 binder (<xref ref-type="supplementary-material" rid="SD3">Fig. S7B</xref>). Notably, dasatinib was not identified as a hit despite being included in libraries used by Schuller et al. One possibility is that dasatinib produced high fluorescence when mixed with SYPRO Orange, a dye commonly used in differential scanning fluorimetry (<xref ref-type="supplementary-material" rid="SD3">Fig. S7C</xref>) and may therefore be a false negative in prior screens. These findings collectively highlight the novelty and benefits of our functional screening approach as a complement to existing screens that assay binding.</p>
<p id="P18">In summary, we have established a new functional assay to identify ADP-ribosylhydrolase inhibitors. Our facile and versatile assay identifies both specific and general ADP-ribosylhydrolase inhibitors. Our pilot screen identified dasatinib, whose selectivity demonstrates it is possible to discover drugs that specifically inhibit viral macrodomains. Although cytotoxic when used at μM concentration,<sup>
<xref ref-type="bibr" rid="R28">28</xref>
</sup> dasatinib has antiviral activities against SARS-CoV and MERS-CoV through an unknown mechanism.<sup>
<xref ref-type="bibr" rid="R29">29</xref>
</sup> Therefore, data presented in this study provide strong support for our target and assay strategy, which can be applied to a large-scale high-throughput screen for new and improved viral macrodomain inhibitors. As the macrodomain fold is highly conserved in all coronaviruses and alphaviruses, this screening tool represents an important step towards developing new broad-spectrum antivirals.</p>
</sec>
<sec sec-type="supplementary-material" id="SM">
<title>Supplementary Material</title>
<p id="P19">Materials and Methods; <xref ref-type="supplementary-material" rid="SD3">Supplementary Figures 1-7</xref>: Sequence alignment of coronavirus macrodomains, enzymatic and structural comparisons of SARS-CoV-2 Mac1 and MacroD2, optimizing assay parameters for drug screening, evaluation of pilot screen hits, surface plasmon resonance traces, molecular docking of dasatinib with SARS-CoV-2 Mac1, comparison of dasatinib with hits identified in previously published screens (PDF).</p>
<supplementary-material content-type="local-data" id="SD1">
<label>Conservation of SARS-CoV-2 genomes</label>
<media xlink:href="EMS136378-supplement-Conservation_of_SARS_CoV_2_genomes.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="N66283" position="anchor"/>
</supplementary-material>
<supplementary-material content-type="local-data" id="SD2">
<label>Pilot screen raw data</label>
<media xlink:href="EMS136378-supplement-Pilot_screen_raw_data.xlsx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.spreadsheetml.sheet" id="N66292" position="anchor"/>
</supplementary-material>
<supplementary-material content-type="local-data" id="SD3">
<label>Supporting Information</label>
<media xlink:href="EMS136378-supplement-Supporting_Information.pdf" mimetype="application" mime-subtype="pdf" id="N66301" position="anchor"/>
</supplementary-material>
</sec>
</body>
<back>
<ack id="S2">
<title>Acknowledgement</title>
<p>We thank Drs Diane Griffin, Mohsen Badiee, Rachy Abraham for their critiques of the manuscript, the NudF expression construct from Dr. Sandra Gabelli, Lauren Bambarger for the initial testing of the luminescence-based assay, and Dr. Said Goueli for advice on the AMP-Glo assay.</p>
<sec id="S3">
<title>Funding Sources</title>
<p>The work is supported by the COVID-19 PreClinical Research Discovery Fund from Johns Hopkins University (A.K.L.L.) and Johns Hopkins Bloomberg School of Public Health Development Fund (A.K.L.L.).</p>
</sec>
</ack>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term>ADP</term>
<def>
<p>adenosine diphosphate</p>
</def>
</def-item>
<def-item>
<term>SARS</term>
<def>
<p>severe acute respiratory syndrome</p>
</def>
</def-item>
<def-item>
<term>MERS</term>
<def>
<p>middle east respiratory syndrome</p>
</def>
</def-item>
<def-item>
<term>CoV</term>
<def>
<p>coronavirus</p>
</def>
</def-item>
<def-item>
<term>HIV</term>
<def>
<p>human immunodeficiency virus</p>
</def>
</def-item>
</def-list>
</glossary>
<fn-group>
<fn id="FN1" fn-type="con">
<p id="P20">Author Contributions</p>
<p id="P21">M.D., J.Z., J.A.G. and A.T. contributed equally to this work, and other contributions as follows: study conception: A.K.L.L.; research design: A.K.L.L., M.D., R.L.M., T.T., B.S., H.W; data collection: M.D., J.Z., J.A.G., A.T., A.K.J., K.R.R., J.B.; reagent generation: R.L.M., S-J.C., B.A.M; data analyses, V.F.B., K.R.R, J.B.; analysis and interpretation of results: M.D., J.B., H.W., A.K.L.L.; draft manuscript preparation: M.D. and A.K.L.L. All authors reviewed the results and approved the final version of the manuscript.</p>
</fn>
<fn id="FN2" fn-type="conflict">
<p id="P22">Notes</p>
<p id="P23">The authors declare no competing financial interest.</p>
</fn>
</fn-group>
<ref-list>
<ref id="R1">
<label>(1)</label>
<element-citation publication-type="journal">
<collab>Coronaviridae Study Group of the International Committee on Taxonomy of Viruses</collab>
<article-title>The Species Severe Acute Respiratory Syndrome-Related Coronavirus:Classifying 2019-NCoV and Naming It SARS-CoV-2</article-title>
<source>Nat Microbiol</source>
<year>2020</year>
<volume>5</volume>
<issue>4</issue>
<fpage>536</fpage>
<lpage>544</lpage>
</element-citation>
</ref>
<ref id="R2">
<label>(2)</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shyr</surname>
<given-names>ZA</given-names>
</name>
<name>
<surname>Gorshkov</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>CZ</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Drug Discovery Strategies for SARS-CoV-2</article-title>
<source>J Pharmacol Exp Ther</source>
<year>2020</year>
<volume>375</volume>
<issue>1</issue>
<fpage>127</fpage>
<lpage>138</lpage>
</element-citation>
</ref>
<ref id="R3">
<label>(3)</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rack</surname>
<given-names>JGM</given-names>
</name>
<name>
<surname>Perina</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ahel</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Macrodomains: Structure, Function, Evolution, and Catalytic Activities</article-title>
<source>Annu Rev Biochem</source>
<year>2016</year>
<volume>85</volume>
<fpage>431</fpage>
<lpage>454</lpage>
</element-citation>
</ref>
<ref id="R4">
<label>(4)</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fehr</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Jankevicius</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Ahel</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Perlman</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Viral Macrodomains:Unique Mediators of Viral Replication and Pathogenesis</article-title>
<source>Trends Microbiol</source>
<year>2018</year>
<volume>26</volume>
<issue>7</issue>
<elocation-id>598610</elocation-id>
</element-citation>
</ref>
<ref id="R5">
<label>(5)</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leung</surname>
<given-names>AKL</given-names>
</name>
<name>
<surname>McPherson</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Griffin</surname>
<given-names>DE</given-names>
</name>
</person-group>
<article-title>Macrodomain ADP-Ribosylhydrolase and the Pathogenesis of Infectious Diseases</article-title>
<source>PLoS Pathog</source>
<year>2018</year>
<volume>14</volume>
<issue>3</issue>
<elocation-id>e1006864</elocation-id>
</element-citation>
</ref>
<ref id="R6">
<label>(6)</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haikarainen</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Lehtiö</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Proximal ADP-Ribose Hydrolysis in Trypanosomatids Is Catalyzed by a Macrodomain</article-title>
<source>Sci Rep</source>
<year>2016</year>
<volume>6</volume>
<issue>1</issue>
<elocation-id>24213</elocation-id>
</element-citation>
</ref>
<ref id="R7">
<label>(7)</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cho</surname>
<given-names>C-C</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>M-H</given-names>
</name>
<name>
<surname>Chuang</surname>
<given-names>C-Y</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>C-H</given-names>
</name>
</person-group>
<article-title>Macro Domain from Middle East Respiratory Syndrome Coronavirus(MERS-CoV) Is an Efficient ADP-Ribose Binding Module: CRYSTAL STRUCTURE AND BIOCHEMICAL STUDIES</article-title>
<source>J Biol Chem</source>
<year>2016</year>
<volume>291</volume>
<issue>10</issue>
<fpage>4894</fpage>
<lpage>4902</lpage>
</element-citation>
</ref>
<ref id="R8">
<label>(8)</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosenthal</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Feijs</surname>
<given-names>KLH</given-names>
</name>
<name>
<surname>Frugier</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bonalli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Forst</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Imhof</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Winkler</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Fischer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Caflisch</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hassa</surname>
<given-names>PO</given-names>
</name>
<name>
<surname>Lüscher</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>
<article-title>MacrodomainContaining Proteins Are New Mono-ADP-Ribosylhydrolases</article-title>
<source>Nat Struct Mol Biol</source>
<year>2013</year>
</element-citation>
</ref>
<ref id="R9">
<label>(9)</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jankevicius</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Hassler</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Golia</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Rybin</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Zacharias</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Timinszky</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Ladurner</surname>
<given-names>AG</given-names>
</name>
</person-group>
<article-title>A Family of Macrodomain Proteins Reverses Cellular Mono-ADP-Ribosylation</article-title>
<source>Nat Struct Mol Biol</source>
<year>2013</year>
</element-citation>
</ref>
<ref id="R10">
<label>(10)</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Debing</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Jankevicius</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Neyts</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ahel</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Coutard</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Canard</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Viral Macro Domains Reverse Protein ADP-Ribosylation</article-title>
<source>J Virol</source>
<year>2016</year>
<volume>90</volume>
<issue>19</issue>
<fpage>8478</fpage>
<lpage>8486</lpage>
</element-citation>
</ref>
<ref id="R11">
<label>(11)</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McPherson</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Abraham</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Sreekumar</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ong</surname>
<given-names>S-E</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>S-J</given-names>
</name>
<name>
<surname>Baxter</surname>
<given-names>VK</given-names>
</name>
<name>
<surname>Kistemaker</surname>
<given-names>HAV</given-names>
</name>
<name>
<surname>Filippov</surname>
<given-names>DV</given-names>
</name>
<name>
<surname>Griffin</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>AKL</given-names>
</name>
</person-group>
<article-title>ADP-Ribosylhydrolase Activity of Chikungunya Virus Macrodomain Is Critical for Virus Replication and Virulence</article-title>
<source>Proc Natl Acad Sci U S A</source>
<year>2017</year>
<volume>114</volume>
<issue>7</issue>
<fpage>1666</fpage>
<lpage>1671</lpage>
</element-citation>
</ref>
<ref id="R12">
<label>(12)</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eckei</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Krieg</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bütepage</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lehmann</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gross</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lippok</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Grimm</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Kümmerer</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Rossetti</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Lüscher</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Verheugd</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>
<article-title>The Conserved Macrodomains of the Non-Structural Proteins of Chikungunya Virus and Other Pathogenic Positive Strand RNA Viruses Function as Mono-ADP-Ribosylhydrolases</article-title>
<source>Sci Rep</source>
<year>2017</year>
<volume>7</volume>
<elocation-id>41746</elocation-id>
</element-citation>
</ref>
<ref id="R13">
<label>(13)</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fehr</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Channappanavar</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Jankevicius</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Fett</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Athmer</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Meyerholz</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Ahel</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Perlman</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>The Conserved Coronavirus Macrodomain Promotes Virulence and Suppresses the Innate Immune Response during Severe Acute Respiratory Syndrome Coronavirus Infection</article-title>
<source>MBio</source>
<year>2016</year>
<volume>7</volume>
<issue>6</issue>
<pub-id pub-id-type="doi">10.1128/mBio.01721-16</pub-id>
</element-citation>
</ref>
<ref id="R14">
<label>(14)</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frick</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Virdi</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Vuksanovic</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Dahal</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Silvaggi</surname>
<given-names>NR</given-names>
</name>
</person-group>
<article-title>Molecular Basis for ADP-Ribose Binding to the Mac1 Domain of SARS-CoV-2 Nsp3</article-title>
<source>Biochemistry</source>
<year>2020</year>
<fpage>2608</fpage>
<lpage>2615</lpage>
<pub-id pub-id-type="doi">10.1021/acs.biochem.0c00309</pub-id>
</element-citation>
</ref>
<ref id="R15">
<label>(15)</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rack</surname>
<given-names>JGM</given-names>
</name>
<name>
<surname>Zorzini</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Schuller</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ahel</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ahel</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Viral Macrodomains: A Structural and Evolutionary Assessment of the Pharmacological Potential</article-title>
<source>Open Biol</source>
<year>2020</year>
<volume>10</volume>
<issue>11</issue>
<elocation-id>200237</elocation-id>
</element-citation>
</ref>
<ref id="R16">
<label>(16)</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alhammad</surname>
<given-names>YMO</given-names>
</name>
<name>
<surname>Kashipathy</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Roy</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gagné</surname>
<given-names>J-P</given-names>
</name>
<name>
<surname>McDonald</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Nonfoux</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Battaile</surname>
<given-names>KP</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Holmstrom</surname>
<given-names>ED</given-names>
</name>
<name>
<surname>Poirier</surname>
<given-names>GG</given-names>
</name>
<etal/>
</person-group>
<article-title>The SARS-CoV-2 Conserved Macrodomain Is a Mono-ADP-Ribosylhydrolase</article-title>
<source>J Virol</source>
<year>2020</year>
<pub-id pub-id-type="doi">10.1128/JVI.01969-20</pub-id>
</element-citation>
</ref>
<ref id="R17">
<label>(17)</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>M-H</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>S-C</given-names>
</name>
<name>
<surname>Chiu</surname>
<given-names>Y-C</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>B-C</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>T-H</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>C-H</given-names>
</name>
</person-group>
<article-title>Structural, Biophysical, and Biochemical Elucidation of the SARS-CoV-2 Nonstructural Protein 3 Macro Domain</article-title>
<source>ACS Infect Dis</source>
<year>2020</year>
<volume>6</volume>
<issue>11</issue>
<elocation-id>29702978</elocation-id>
</element-citation>
</ref>
<ref id="R18">
<label>(18)</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abraham</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hauer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>McPherson</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Utt</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kirby</surname>
<given-names>IT</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Merits</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>AKL</given-names>
</name>
<name>
<surname>Griffin</surname>
<given-names>DE</given-names>
</name>
</person-group>
<article-title>ADP-Ribosyl-Binding and Hydrolase Activities of the AlphavirusNsP3 Macrodomain Are Critical for Initiation of Virus Replication</article-title>
<source>Proc Natl Acad Sci U S A</source>
<year>2018</year>
<volume>115</volume>
<issue>44</issue>
<fpage>E10457</fpage>
<lpage>E10466</lpage>
</element-citation>
</ref>
<ref id="R19">
<label>(19)</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abraham</surname>
<given-names>R</given-names>
</name>
<name>
<surname>McPherson</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Dasovich</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Badiee</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>AKL</given-names>
</name>
<name>
<surname>Griffin</surname>
<given-names>DE</given-names>
</name>
</person-group>
<article-title>Both ADP-Ribosyl-Binding and Hydrolase Activities of the Alphavirus NsP3 Macrodomain Affect Neurovirulence in Mice</article-title>
<source>MBio</source>
<year>2020</year>
<volume>11</volume>
<issue>1</issue>
<pub-id pub-id-type="doi">10.1128/mBio.03253-19</pub-id>
</element-citation>
</ref>
<ref id="R20">
<label>(20)</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eriksson</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Cervantes-Barragán</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ludewig</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Thiel</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Mouse Hepatitis Virus Liver Pathology Is Dependent on ADP-Ribose-1”-Phosphatase, a Viral Function Conserved in the Alpha-like Supergroup</article-title>
<source>J Virol</source>
<year>2008</year>
<volume>82</volume>
<issue>24</issue>
<fpage>12325</fpage>
<lpage>12334</lpage>
</element-citation>
</ref>
<ref id="R21">
<label>(21)</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Voth</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>‘Connor</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Kerr</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Doerger</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Schwarting</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sperstad</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Fehr</surname>
<given-names>AR</given-names>
</name>
</person-group>
<article-title>An MHV Macrodomain Mutant Predicted to Lack ADP-Ribose BindingActivity Is Severely Attenuated, Indicating Multiple Roles for the Macrodomain in Coronavirus Replication</article-title>
<source>Cold Spring Harbor Laboratory</source>
<year>2021</year>
<elocation-id>2021.03.30.437796</elocation-id>
<pub-id pub-id-type="doi">10.1101/2021.03.30.437796</pub-id>
</element-citation>
</ref>
<ref id="R22">
<label>(22)</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jayabalan</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Adivarahan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Koppula</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Abraham</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Batish</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zenklusen</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Griffin</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>AKL</given-names>
</name>
</person-group>
<article-title>Stress Granule Formation, Disassembly, and Composition Are Regulated by Alphavirus ADP-Ribosylhydrolase Activity</article-title>
<source>Proc Natl Acad Sci U S A</source>
<year>2021</year>
<volume>118</volume>
<issue>6</issue>
<pub-id pub-id-type="doi">10.1073/pnas.2021719118</pub-id>
</element-citation>
</ref>
<ref id="R23">
<label>(23)</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Daniels</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Thirawatananond</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ong</surname>
<given-names>S-E</given-names>
</name>
<name>
<surname>Gabelli</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>AKL</given-names>
</name>
</person-group>
<article-title>Nudix Hydrolases Degrade Protein-Conjugated ADP-Ribose</article-title>
<source>Sci Rep</source>
<year>2015</year>
<volume>5</volume>
<elocation-id>18271</elocation-id>
</element-citation>
</ref>
<ref id="R24">
<label>(24)</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baell</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Holloway</surname>
<given-names>GA</given-names>
</name>
</person-group>
<article-title>New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays</article-title>
<source>J Med Chem</source>
<year>2010</year>
<volume>53</volume>
<issue>7</issue>
<fpage>2719</fpage>
<lpage>2740</lpage>
</element-citation>
</ref>
<ref id="R25">
<label>(25)</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schuller</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Correy</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Gahbauer</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fearon</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Díaz</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>ID</given-names>
</name>
<name>
<surname>Martins</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Schulze-Gahmen</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Owens</surname>
<given-names>TW</given-names>
</name>
<etal/>
<collab>QCRG Structural Biology Consortium</collab>
</person-group>
<article-title>Fragment Binding to the Nsp3 Macrodomain of SARS-CoV-2 Identified through Crystallographic Screening and Computational Docking</article-title>
<source>Science Advances</source>
<year>2021</year>
<volume>7</volume>
<issue>16</issue>
<elocation-id>eabf8711</elocation-id>
</element-citation>
</ref>
<ref id="R26">
<label>(26)</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Virdi</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Bavisotto</surname>
<given-names>RV</given-names>
</name>
<name>
<surname>Hopper</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Vuksanovic</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Melkonian</surname>
<given-names>TR</given-names>
</name>
<name>
<surname>Silvaggi</surname>
<given-names>NR</given-names>
</name>
<name>
<surname>Frick</surname>
<given-names>DN</given-names>
</name>
</person-group>
<article-title>Discovery of Drug-Like Ligands for the Mac1 Domain of SARS-CoV-2 Nsp3</article-title>
<source>SLAS Discov</source>
<year>2020</year>
<volume>25</volume>
<issue>10</issue>
<fpage>1162</fpage>
<lpage>1170</lpage>
</element-citation>
</ref>
<ref id="R27">
<label>(27)</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bajusz</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wade</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Satała</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Bojarski</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Ilaš</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ebner</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Grebien</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Papp</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Jakab</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Douangamath</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fearon</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>
<article-title>Exploring Protein Hotspots by Optimized Fragment Pharmacophores</article-title>
<source>Nat Commun</source>
<year>2021</year>
<volume>12</volume>
<issue>1</issue>
<fpage>3201</fpage>
</element-citation>
</ref>
<ref id="R28">
<label>(28)</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hochhaus</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kantarjian</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Baccarani</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lipton</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Apperley</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Druker</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Facon</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Goldberg</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Cervantes</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Niederwieser</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Silver</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Stone</surname>
<given-names>RM</given-names>
</name>
<etal/>
</person-group>
<article-title>Dasatinib Induces Notable Hematologic and Cytogenetic Responses in Chronic-Phase Chronic Myeloid Leukemia after Failure of Imatinib Therapy</article-title>
<source>Blood</source>
<year>2007</year>
<volume>109</volume>
<issue>6</issue>
<fpage>2303</fpage>
<lpage>2309</lpage>
</element-citation>
</ref>
<ref id="R29">
<label>(29)</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dyall</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Coleman</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Hart</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Venkataraman</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Holbrook</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Kindrachuk</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>RF</given-names>
</name>
<name>
<surname>Olinger</surname>
<given-names>GGJr</given-names>
</name>
<name>
<surname>Jahrling</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Laidlaw</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Johansen</surname>
<given-names>LM</given-names>
</name>
<etal/>
</person-group>
<article-title>Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection</article-title>
<source>Antimicrob Agents Chemother</source>
<year>2014</year>
<volume>58</volume>
<issue>8</issue>
<fpage>4885</fpage>
<lpage>4893</lpage>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="F1" position="float">
<label>Fig. 1</label>
<caption>
<title>Biochemical, enzymatic, and structural characterization of SARS-CoV-2 Mac1 and human MacroD2.</title>
<p>
<bold>(A)</bold> Gel-based ADP-ribosylhydrolase assay against a mono-ADP-ribosylated substrate. Mono-ADP-ribose signal was normalized to the buffer signal. Plotted values are mean ± S.D. (n = 3). <bold>(B)</bold> Schematic of the luminescence-based ADP-ribosylhydrolase assay, ADPr-Glo. <bold>(C-D)</bold> Michaelis-Menten kinetics characterization of (C) Mac1 and (D) MacroD2 (n = 12, four technical replicates from three experiments, gray area is S.D.). <bold>(E)</bold> Electrophoretic mobility shift assay (EMSA) analyses of Mac1 and MacroD2 binding on Cy5-PAR. Plotted values are mean ± S.D., n = 3. <bold>(F)</bold> Surface representation of the conservation between Mac1 and MacroD2. Bound ADP-ribose is shown as stick representation. <bold>(G)</bold> Zoom-in view of the electrostatic surface potential of the ADP-ribose binding site for Mac1 (top) and MacroD2 (bottom).</p>
</caption>
<graphic xlink:href="EMS136378-f001"/>
</fig>
<fig id="F2" position="float">
<label>Fig. 2</label>
<caption>
<title>Pilot screen for macrodomain inhibitors.</title>
<p>(A) Schematic of the drug screen based on the ADP-ribosylhydrolase assay ADPr-Glo. (B) Coefficients of variation (CV) and Z’ values for each plate in the screen. (C) Z scores for the 3,233 compounds evaluated.</p>
</caption>
<graphic xlink:href="EMS136378-f002"/>
</fig>
<fig id="F3" position="float">
<label>Fig. 3</label>
<caption>
<title>Dasatinib inhibits SARS-CoV-2 Mac1, but not human MacroD2.</title>
<p>(<bold>A-B</bold>) Dose-response curves for (A) dasatinib and (B) dihydralazine against SARS-CoV-2 Mac1 and MacroD2. Plotted values are mean ± S.D. (n = 4). (<bold>C</bold>) Gel-based assay demonstrating inhibition of Mac1 by dasatinib (n = 2). (<bold>D-E</bold>) SPR analyses of (D) ADP-ribose and (E) dasatinib binding to Mac1 wild-type (WT) and G252E as well as MacroD2. The binding was quantitated by the Area Under Curve (AUC) normalized by the maximal response unit (R<sub>max</sub>). (<bold>F</bold>) Molecular docking of dasatinib to Mac1. (<bold>G</bold>) Structure-based sequence alignment of Mac1 and MacroD2 with contacting residues to ADP-ribose (green) and dasatinib, where red and blue indicates hydrophobic and hydrogen-bond (e.g., Asp 226 and Leu 330) interactions, respectively. (<bold>H</bold>) Analyses of 440,212 SARS-CoV-2 genomes revealed the dasatinib docking site is highly conserved. No residues within 5Å near the docking site have high mutation frequencies. (<bold>I</bold>) Comparison of dasatinib with other macrodomain inhibitor hits using ADPr-Glo with 100 μM inhibitor.</p>
</caption>
<graphic xlink:href="EMS136378-f003"/>
</fig>
</floats-group>
</article>
